Document:

EX-10.26

 Exhibit 10.26 
  

 
 255 State Street, 9th Floor 

Boston, MA 02109
 February 7, 2017

 VIA EMAIL 

Darlene Deptula-Hicks 
  

	 	Re:	Separation Agreement 

 Dear Darlene: 

The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your separation from Pieris Pharmaceuticals,
Inc. (“Pieris” or the “Company”). Payment of the Separation Benefit described below is contingent on your agreement to and compliance with the terms of this Agreement. This Agreement shall become effective on the date that is the
eighth (8th) day following your execution of it, as explained more fully in Section 6 below (the “Effective Date”). 

1.    Separation of Employment. As we discussed, your employment with Pieris ended effective
February 7, 2017 (the “Separation Date”). From and after the Separation Date, you shall not represent yourself or perform services as an employee of Pieris. As of the Separation Date, all salary payments from the Company shall cease
and any benefits you currently have under Company-provided benefit plans, programs, or practices shall terminate, except as required by federal or state law or as otherwise set forth herein. The Company shall provide you with all wages owed through
the Separation Date (including accrued but unused vacation time), and shall pay all normal and reasonable business expenses that you have incurred or shall incur in the ordinary course through the Separation Date. Receipts for any outstanding
business expenses shall be submitted within ten (10) days of the date hereof. By executing this Agreement, you hereby resign from any other positions, offices or directorships you may have with the Company or any of its subsidiaries or
affiliates. 
 2.    Separation Benefit. In exchange for the promises and covenants
contained herein, including but not limited to your release of claims, Pieris agrees to provide you with the following: 

(a)    Severance Payments. Pieris shall provide you with (i) severance pay in the form of continued
payment of your gross bi-weekly Base Salary (as defined in your August 27, 2015 employment agreement with the Company, the “Employment Agreement”), less applicable

  
 1 

 
withholdings and deductions, for a period of twelve (12) months, commencing with the Company’s first payroll date following the Effective Date; and (ii) a payment for the full
Target Bonus Amount of your 2016 annual discretionary bonus (i.e., $120,000), in the form of one (1) lump-sum payment, less applicable withholdings and deductions, to be paid on the Company’s first
payroll date following the Effective Date. You acknowledge and agree that you have not earned and are not owed any portion of the Target Bonus Amount of your 2017 annual discretionary bonus. 

(b)    Attorneys’ Fees. The Company shall reimburse you for up to $3,500 in documented attorneys’
fees related to the review and negotiation of this Agreement. Such reimbursement shall be paid in accordance with applicable expense reimbursement policies; provided, however, that all reimbursements under this Section 2(b) shall be made in the 2017
calendar year. 
 (c)    Vesting of Options and Extension of Exercise Period. You have been granted a non-qualified stock option to purchase 450,000 shares of the Company’s common stock (the “Option”) pursuant to the terms of a Stock Option Agreement dated September 1, 2015 (as amended on
April 8, 2016, the “Option Agreement”), and the terms of the Company’s 2016 Equity Employee, Director and Consultant Incentive Plan (the “Plan”). As of the Separation Date, 159,960 of the shares subject to the
Option are vested, and 290,040 of the shares subject to the Option are unvested (the “Unvested Shares”). 
  

	 	i.	Pieris shall accelerate the vesting of 25% of your Unvested Shares, such that your Option to purchase a total of 232,470 shares of Pieris common stock subject to the Stock Option Agreement and the Plan shall be vested
(the “Vested Option”) and exercisable as of the Effective Date. 

  

	 	ii.	The Company hereby agrees to extend the exercise period of the Vested Option to twelve (12) months following the Separation Date (the “Exercise Period”) or such shorter period as set forth in
Section 24 of the Plan. 

  

	 	iii.	You and the Company hereby agree that, in connection with any exercise of the Vested Option during the Exercise Period, you shall pay for the exercise price (but not any amounts withheld or to otherwise cover any tax
obligation with respect thereto) of the Vested Option by “net exercise” as set forth in Section 10 of the Plan. 

  

	 	iv.	You agree that during the Exercise Period, you shall not, without the written consent of the Company, sell, assign, transfer, encumber, establish a short position or otherwise hedge or dispose of more than 50,000 shares
of the Company’s common stock per each rolling thirty (30) day period. Upon the completion of the Exercise Period, you will be free to transfer or dispose of the Company’s common stock without limitation, except that all such
transfers or dispositions shall be in compliance with applicable securities laws, including, but not limited to, the insider trading rules promulgated by the Securities and Exchange Commission. 

 

	 	v.	 You acknowledge and agree that the unvested portion of the Option for 217,530 shares (the “Unvested
Option”) is hereby terminated as of the Separation Date in accordance with the terms of the Option Agreement and the Plan, and you shall have no right(s) to exercise any portion of the

  
 2 

	 	
Unvested Option following the Separation Date. You acknowledge and agree that the Company does not guarantee or make any representations regarding the tax consequences or tax treatment of the
Vested Option. Except as modified herein, the terms and conditions of the Plan and the Stock Option Agreement are incorporated herein by reference and shall survive the signing of this Agreement. 

(d)    Continued Healthcare. By law, and regardless of whether you sign this Agreement, you shall have the
right to continue your medical and dental insurance pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”). The COBRA qualifying event shall be deemed to have occurred on March 1, 2017. Upon
completion of the appropriate COBRA forms and your execution of this Agreement, and subject to all the requirements of COBRA, you shall be allowed to continue participation in the Company’s health and dental insurance plans at the
Company’s expense (except for your co-pay or your portion of premium payments, if any, which shall be paid directly by you), for the period commencing on the first day of the full calendar month following
the Effective Date and irrevocable through the earlier of (i) the last day of the twelve (12) full calendar months following the Effective Date and (i) the date you and your covered dependents, if any, become eligible healthcare
coverage under another employer’s plan(s). You agree to provide the Company with written notice immediately upon securing such employment and upon becoming eligible for such benefits. Thereafter, your eligibility to continue participation in
the Company’s health and dental insurance plans under COBRA (including but not limited to the COBRA premium payments required for same) shall be subject to COBRA rules and provisions. 

The payments and benefits provided under this Section 2 shall be referred to as the “Separation Benefit.” You acknowledge and
agree that the Separation Benefit is not otherwise due or owing to you under any Pieris policy or practice. For the avoidance of doubt, the above-described Separation Benefit shall be in lieu of (and not in addition to) any payments or benefits
described in Section 4(b) of the Employment Agreement. You further acknowledge that except for the Separation Benefit, your final wages, any accrued but unused vacation, and any properly incurred but not yet reimbursed business expenses (each of
which shall be paid or reimbursed, as the case may be, in accordance with Pieris’ regular payroll practices and applicable law), you are not now and shall not in the future be entitled to any other compensation from Pieris including, without
limitation, other wages, commissions, bonuses, vacation pay, holiday pay, equity, stock, stock options, paid time off, or any other form of compensation or benefit. 

3.    Cooperation. You shall cooperate fully with Pieris in connection with any matter or
event relating to your employment or events that occurred during your employment, including, without limitation: (a) being available upon reasonable notice to meet with Pieris regarding matters in which you have been involved (including
contract matters or audits); (b) assisting Pieris in transitioning your job duties to other Pieris personnel or contractors; (c) assisting with any audit, inspection, proceeding or other inquiry by a private or public entity; and
(d) as requested by Pieris, assisting in the defense or prosecution of any claims or actions now in existence or which may be brought or threatened in the future against or on behalf of Pieris (including claims or actions against
its affiliates and its and their officers and employees), including acting as a witness, providing affidavits, and preparing for, attending and participating in any legal proceeding (including depositions, consultation, discovery or trial) in
connection with such claim or action. You further agree that should you be contacted (directly or indirectly) by any person or entity (for example, by any party representing an individual or entity) adverse to the Company, you shall promptly notify
the President and Chief Executive Officer of the Company. You shall be reimbursed for any reasonable out-of-pocket costs and expenses approved in advance by Pieris and
incurred in connection with providing such cooperation under this Section 3. 

  
 3 

 4.    Your Additional Covenants. You expressly
acknowledge and agree to the following: 
 (a)    You shall adhere to the ongoing obligations in your Employment
Agreement (including, but not limited to, Section 4(a)), the Corporate Code of Conduct and Ethics, Whistleblower Policy and Insider Trading Policy between you and the Company regarding confidential information, intellectual property, and non-competition and non-solicitation (the “Agreements”), the terms of which are incorporated herein and shall survive the signing of this Agreement. 

(b)    You shall promptly return to the Company all Company documents (and any copies thereof), equipment and
property, and you shall abide by any and all common law and statutory obligations relating to protection of the Company’s trade secrets and confidential and proprietary information. 

(c)    In the event that you receive an order, subpoena, request, or demand for disclosure of the Company’s
trade secrets and/or confidential and proprietary documents and information from any court or governmental agency, or from a party to any litigation or administrative proceeding, you shall notify the Company of same as soon as reasonably possible
and prior to disclosure, in order to provide the Company with the opportunity to assert its respective interests in addressing or opposing such order, subpoena, request, or demand. 

(d)    All information relating in any way to the negotiation of this Agreement, including the terms and amount of
financial consideration provided for in this Agreement, shall be held confidential by you and shall not be publicized or disclosed to any person (other than an immediate family member, legal counsel or financial advisor, provided that any such whom
disclosure is made agrees to be bound by these confidentiality obligations), to any government agency (except as mandated by state or federal law), or to any business entity. 

(e)    You shall not make any statements that are disparaging about the Company or its officers, directors,
managers or employees, including, but not limited to, any statements that disparage any program, service, finances, financial condition, capability or any other aspect of the business of the Company, and you shall not engage in any conduct which is
intended to harm professionally or personally the reputation of the Company or its officers, directors, managers or employees. The Company agrees that its executive management team and members of its board of directors will not make any statements
that are disparaging about you and will not engage in any conduct which is intended to harm professionally or personally your reputation. In response to inquiries from third parties concerning your employment and/or departure, the Company’s
response will be consistent with the substance of the press release issued by the Company in connection with your departure. 

(f)    A breach of any provision of this Section 4 shall constitute a material breach of this Agreement and,
in addition to any other legal or equitable remedy available to the Company, shall entitle the Company to recover the Separation Benefit provided to you under this Agreement. 

  
 4 

 5.    Your Release of Claims. 

(a)    Release. You hereby agree that by signing this Agreement and accepting the Separation Pay, Separation
Benefits and other good and valuable consideration provided for in this Agreement, you are waiving and releasing your right to assert any form of legal claim against the Company1/ whatsoever for
any alleged action, inaction or circumstance existing or arising from the beginning of time through the Effective Date. Your waiver and release herein is intended to bar any form of legal claim, charge, complaint or any other form of action (jointly
referred to as “Claims”) against the Company seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages or any other form of monetary recovery
whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys’ fees and any other costs) against the Company, for any alleged action, inaction or circumstance
existing or arising through the Effective Date. Without limiting the foregoing general waiver and release, you specifically waive and release the Company from any Claim arising from or related to your employment relationship with the Company or the
termination thereof, including, without limitation: 
 (i)    Claims under any state or federal statute,
regulation or executive order (as amended through the Effective Date) relating to employment, discrimination, fair employment practices, or other terms and conditions of employment, including but not limited to the Age Discrimination in Employment
Act and Older Workers Benefit Protection Act (29 U.S.C. § 621 et seq.), the Civil Rights Acts of 1866 and 1871 and Title VII of the Civil Rights Act of 1964 and the Civil Rights Act of 1991 (42 U.S.C. § 2000e et seq.), the Equal Pay Act
(29 U.S.C. § 201 et seq.), the Americans With Disabilities Act (42 U.S.C. § 12101 et seq.), the Genetic Information Non-Discrimination Act (42 U.S.C. §2000ff et seq.), the Massachusetts Fair
Employment Practices Statute (M.G.L. c. 151B § 1 et seq.), the Massachusetts Equal Rights Act (M.G.L. c. 93 §102), the Massachusetts Civil Rights Act (M.G.L. c. 12 §§ 11H & 11I), the Massachusetts Privacy Statute (M.G.L.
c. 214 § 1B), the Massachusetts Sexual Harassment Statute (M.G.L. c. 214 § 1C), and any similar Massachusetts or other state or federal statute. 

(ii)    Claims under any state or federal statute, regulation or executive order (as amended through the Effective
Date) relating to leaves of absence, layoffs or reductions-in-force, wages, hours, or other terms and conditions of employment, including but not limited to the National
Labor Relations Act (29 U.S.C. § 151 et seq.), the Family and Medical Leave Act (29 U.S.C. §2601 et seq.), the Employee Retirement Income Security Act of 1974 (29 U.S.C. § 1000 et seq.), COBRA (29 U.S.C. § 1161 et seq.), the
Worker Adjustment and Retraining Notification Act (29 U.S.C. § 2101 et seq.), the Uniformed Services Employment and Reemployment Rights Act of 1994 (38 U.S.C. § 4301 et seq.), the Massachusetts Wage Act (M.G.L. c. 149 § 148 et. seq.),
the Massachusetts Minimum Fair Wages Act (M.G.L. c. 151 § 1 et. seq.), the Massachusetts Equal Pay Act (M.G.L. c. 149 § 105A), and any similar Massachusetts or other state or federal statute. Please note that this section specifically
includes a waiver and release of Claims that you have or may have regarding payments or amounts covered by the Massachusetts Wage Act or the Massachusetts Minimum Fair Wages Act (including, for instance, hourly wages, salary, overtime, minimum
wages, commissions, vacation pay, holiday pay, sick leave pay, dismissal pay, bonus pay or severance pay), as well as Claims for retaliation under the Massachusetts Wage Act or the Massachusetts Minimum Fair Wages Act. 

 
  

	1/ 	For the purposes of this Section 5, the parties agree that the term “Company” shall include Pieris Pharmaceuticals, Inc., its divisions, affiliates, parents and subsidiaries, and any of its and their
respective officers, directors, shareholders, employees, consultants, contractors, attorneys, agents and assigns. 

  
 5 

 (iii)    Claims under any state or federal common law theory,
including, without limitation, wrongful discharge, breach of express or implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, violation of public policy, defamation, interference with
contractual relations, intentional or negligent infliction of emotional distress, invasion of privacy, misrepresentation, deceit, fraud or negligence or any claim to attorneys’ fees under any applicable statute or common law theory of recovery.

 (iv)    Claims under any state or federal statute, regulation or executive order (as amended through the
Effective Date) relating to violation of public policy or any other form of retaliation or wrongful termination, under any federal or any similar Massachusetts or other state or federal statute. 

(v)    Claims under any Company employment, compensation, benefit, stock option, incentive compensation, bonus,
restricted stock, and/or equity plan, program, policy, practice or agreement, including, without limitation the Employment Agreement and the Option Agreement. 

(vi)    Any other Claim arising under any other state or federal law. 

You explicitly acknowledge that because you are over forty (40) years of age, you have specific rights under the ADEA, which prohibits
discrimination on the basis of age, and that the releases set forth in this Section 5 are intended to release any right that you may have to file a claim against the Company alleging discrimination on the basis of age. 

(b)    Release Exclusions. Notwithstanding the foregoing, this Section 5 does not:
(i) release the Company from any obligation expressly set forth in this Agreement or from any obligation, including without limitation obligations under the Workers Compensation laws, which as a matter of law cannot be released;
(ii) release any right to indemnification under the Company’s Bylaws, Articles of Incorporation, and/or directors’ and officers’ liability insurance policies as of the Separation Date, subject to the terms and conditions of same
(iii) prohibit you from filing a charge with the Equal Employment Opportunity Commission (“EEOC”), the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission, or any
other federal, state or local governmental agency or commission (a “Government Agency”); (iv) prohibit you from participating in an investigation or proceeding by a Government Agency, communicating with a Government Agency, or providing
information or documents to a Government Agency; or (v) prohibit you from challenging or seeking a determination in good faith of the validity of this release or waiver under applicable state or federal law, or impose any condition precedent,
penalty, or costs for doing so unless specifically authorized by state or federal law. Your waiver and release, however, are intended to be a complete bar to any recovery or personal benefit by or to you with respect to any claim whatsoever,
including those raised through a charge with the EEOC or comparable federal, state or local governmental agency, except those which, as a matter of law, cannot be released. 

(c)    Acknowledgment. You acknowledge and agree that, but for providing this waiver and release, you would
not be receiving the Separation Benefit being provided to you under the terms of this Agreement. You further agree that should you breach this Section 5, the Company, in addition to any other legal or equitable remedy available to the Company,
shall be entitled to recover any the cost of the Separation Benefit previously provided to you pursuant to Section 2 hereof. 

  
 6 

 6.    ADEA/OWBPA Review and Revocation Period. You and Pieris
acknowledge that you are over the age of 40 and that you, therefore, have specific rights under the Age Discrimination in Employment Act (“ADEA”) and the Older Workers Benefit Protection Act (the “OWBPA”), which prohibit
discrimination on the basis of age. It is Pieris’ desire and intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you have been encouraged and given the opportunity to consult with legal
counsel for the purpose of reviewing the terms of this Agreement. Consistent with the provisions of the ADEA and OWBPA, Pieris also is providing you with twenty one (21) days in which to consider and accept the terms of this Agreement by
signing below and returning it to Stephen S. Yoder, President and Chief Executive Officer, Pieris Pharmaceuticals, Inc., 255 State Street, 9th Floor, Boston, MA 02129. You agree that any modifications, material or otherwise, made to this Agreement
do not and shall not restart or affect in any manner whatsoever, the original 21-day Review Period. You may rescind your assent to this Agreement if, within seven (7) days after you sign this Agreement,
you deliver by hand or send by mail (certified, return receipt and postmarked within such 7-day period) a notice of rescission at the above-referenced address. 

7.    Opportunity to Disclose. You acknowledge that you have been provided the opportunity to advise
the Company as to any concerns regarding its financial statements, SEC filings and other public disclosures or any other matters, and have confirmed to the Company that you have no such concerns. 

8.    Taxes and Withholdings. The Separation Benefit provided under this Agreement shall be
reduced by all applicable federal, state, local and other deductions, taxes, and withholdings. Pieris does not guarantee the tax treatment or tax consequences associated with any payment or benefit under this Agreement, including but not limited to
consequences related to Section 409A of the Code. 
 9.    Modification; Waiver;
Severability. No variations or modifications hereof shall be deemed valid unless reduced to writing and signed by the parties hereto. The failure of Pieris to seek enforcement of any provision of this Agreement in any instance or for
any period of time shall not be construed as a waiver of such provision or of Pieris’ right to seek enforcement of such provision in the future. The provisions of this Agreement are severable, and if for any reason any part hereof shall be
found to be unenforceable, the remaining provisions shall be enforced in full. 
 10.    Choice of Law and
Venue; Jury Waiver. This Agreement shall be deemed to have been made in Massachusetts, shall take effect as an instrument under seal within Massachusetts, and shall be governed by and construed in accordance with the laws of
Massachusetts, without giving effect to conflict of law principles. You agree that any action, demand, claim or counterclaim relating to the terms and provisions of this Agreement, or to its breach, shall be commenced in Massachusetts in a court of
competent jurisdiction, and you further acknowledge that venue for such actions shall lie exclusively in Massachusetts and that material witnesses and documents would be located in Massachusetts. 

11.    Entire Agreement. You acknowledge and agree that this Agreement, along with the specific
agreements that are expressly incorporated herein by reference and stated as surviving the signing of this Agreement, supersede any and all prior or contemporaneous oral and written agreements between you and Pieris, and set forth the entire
agreement between you and Pieris. 

  
 7 

 12.    Knowing and Voluntary Agreement. By
executing this Agreement, you are acknowledging that you have been afforded sufficient time to understand the terms and effects of this Agreement, that your agreements and obligations hereunder are made voluntarily, knowingly and without duress, and
that neither Pieris nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 8 

 This Agreement may be signed on one or more copies, each of which when signed shall be deemed to
be an original, and all of which together shall constitute one and the same Agreement. If the foregoing correctly sets forth our understanding, please sign, date and return the enclosed copy of this Agreement to me. If Pieris does not receive your
acceptance within twenty-one (21) days, the Agreement shall terminate and be of no further force or effect. 

 

			
	Sincerely,
	
	PIERIS PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Stephen S. Yoder

		 	Stephen S. Yoder
		 	President and Chief Executive Officer
		
	Dated:	 	February 7, 2017

  

			
	Agreed and Acknowledged:
	
	 /s/ Darlene Deptula-Hicks

	Darlene Deptula-Hicks
		
	Dated:	 	February 7, 2017

  
 9EX-10.28

 Exhibit 10.28 

EMPLOYMENT AGREEMENT 

This Employment Agreement (the “Agreement”) is made and entered into by and between Claude Knopf
(“Executive”) and Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”) (together referred to herein as the “Parties”), effective as of November 11, 2016 (the
“Effective Date”). 
 R E C I T A L S 

WHEREAS, the Company desires to employ Executive as Sr. Vice President and Chief Business Officer of the Company and Executive desires to
accept such employment, subject to the terms and conditions contained in this Agreement, 
 NOW, THEREFORE, in consideration of the premises
and mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties agree as follows: 

1. Employment. 

(a) Term of Agreement. This Agreement shall become effective on the Effective Date and shall continue unless terminated in accordance
with the terms and conditions contained in Sections 3 and 4 of this Agreement (the “Term”). Executive’s employment shall begin on November 14, 2016, unless otherwise agreed to in writing by the Parties (the “Start
Date”), and at all times shall be “at-will”. 
 (b) Position and Duties. Subject to the terms and conditions of
this Agreement, the Company agrees to employ Executive during the Term as Sr. Vice President and Chief Business Officer of the Company and as such he shall report to the Chief Executive Officer of the Company. Executive shall perform such duties and
bear the responsibilities as are customarily associated with this position as well as such other duties as shall be specified and designated from time to time by the Company’s Chief Executive Officer, his designee, and/or the Company’s
board of directors (the “Board”). 
 (c) Location. Executive shall perform services for the Company at the
Company’s offices located in Boston, MA; provided, however, that the Company may from time to time require Executive to travel to other locations in connection with the Company’s business on a reasonable basis. For purposes
of clarity, Executive is not required to move his office from the Boston Location. 
 (d) Exclusivity. 

(i) During the Term, Executive shall devote all of Executive’s business time and energies to the business and affairs of
Company and its Affiliates and to the faithful and diligent performance of the duties and responsibilities described herein. During the Term, Executive shall not (A) accept any other employment or consultancy or (B) serve on the board of
directors or similar body of any entity, unless such position is approved by the Chief Executive Officer as set forth in subsection (d)(ii) below (which such 

 
approval shall continue until such time as the Company provides notice to Executive that, in its reasonable judgment, such position is with a Competing Entity, interferes with Executive’s
duties to the Company or places Executive in a Competing Position with, or otherwise conflicts with, the interests of the Company, at which time the Company and Executive will discuss such conflict and the parties will use reasonable efforts to
reach agreement on its resolution); provided that Executive may engage in civic and not-for-profit activities, so long as such activities, in the aggregate, do not conflict with the interests of the Company or materially interfere with the
performance of Executive’s duties to the Company and do not otherwise conflict with subsection (d)(ii) below. 
 (ii)
During Executive’s employment by the Company, Executive agrees not to acquire, assume or participate in, directly or indirectly, any financial position, investment or interest known by Executive to be adverse or antagonistic to the Company, its
business or prospects, financial or otherwise or in any Competing Entity, directly or indirectly; provided, however, Executive may accept equity compensation related to the positions or business activities engaged in which have been approved by the
Company pursuant to subsection (d)(i) above. Ownership by Executive, as a passive investment, of less than two percent (2%) of the outstanding shares of capital stock of any corporation with one or more classes of its capital stock listed on a
national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute breach of this Section 1(d). 

(iii) The Executive hereby represents to the Company that: (i) the execution and delivery of this Agreement by the
Executive and the Company and the performance by the Executive of the Executive’s duties hereunder do not and shall not constitute a breach of, conflict with, or otherwise contravene or cause a default under, the terms of any other agreement or
policy to which the Executive is a party or otherwise bound or any judgment, order or decree to which the Executive is subject; (ii) in entering into this Agreement and carrying out Executive’s duties under this Agreement, Executive will
not disclose to the Company any trade secret, confidential or proprietary information belonging to any other Person, including any previous employer, and that Executive shall not bring with Executive any such information to the Company;
(iii) the Executive is not bound by any agreement with any previous employer or other party to refrain from competing with the business of, which would be violated by your employment with the Company; and (iv) all facts Executive has
presented or will present to the Company in connection with entering into this Agreement and an employment relationship with the Company are accurate and true, and this includes all oral and written statements Executive has made to the Company
(including, but not limited to, those pertaining to any agreements Executive previously entered into containing restrictive covenants, Executive’s prior work experience, and Executive’s prior exposure to trade secrets, confidential and
proprietary information), and Executive understands that the Company will rely upon the accuracy and truth of the representations and warranties of the Executive set forth herein and the Executive consents to such reliance. 

  
 - 2 - 

 2. Compensation and Related Matters. 

(a) Base Salary. Executive’s annual base salary (“Base Salary”) will be $370,000 in U.S. Dollars, less payroll
deductions and all required withholdings, payable in accordance with the Company’s normal payroll practices in effect from time to time. The Board or a committee of the Board shall review Executive’s Base Salary at least annually to
determine if adjustments upward to Executive’s Base Salary, if any, will be made solely at the discretion of the Board or a committee of the Board. 

(b) Bonus. Executive shall also be eligible for an annual discretionary bonus of up to 40% of Executive’s then-Base Salary (the
“Target Bonus Amount”) as determined by the Board or a committee of the Board in its sole discretion, based upon the Board’s or a committee of the Board’s evaluation (in its sole discretion) of the achievement of specific
individual and/or Company-wide performance goals as chosen and determined by the Board or a committee of the Board in its sole discretion. The annual discretionary bonus, if any, shall be payable, less authorized deductions and required
withholdings, no later than March 15th of the calendar year immediately following the calendar year in which it was earned. The Target Bonus Amount of any annual discretionary bonus for which
Executive is eligible shall be reviewed by the Board or a committee of the Board from time to time. Notwithstanding the above, the Company, subject to the sole discretion of the CEO and the Board, may increase the Target Bonus Amount. 

(c) Equity Awards. Subject to approval of the Board or an appropriate committee thereof, Company shall grant Executive on the Start
Date or as soon thereafter as practicable, a nonqualified stock option to purchase 500,000 shares of common stock of the Company (the “Option”). Twenty-five percent (25%) of the Option shall vest on the first anniversary of the
Start Date (the “Initial Vesting Date”), with the remaining seventy-five percent (75%) of the Option to vest over the next three years in quarterly installments after the Initial Vesting Date, subject in each case to
Executive’s continued employment in Good Standing. The option shall be evidenced in writing by a stock option agreement, and subject to terms and conditions substantially similar to the Plan and the Company’s standard form of stock option
agreement. The stock option agreement shall expire ten (10) years from the date of grant except as otherwise provided herein or in the stock option agreement. 

(d) Benefits. During the Term, the Company, shall provide Executive with coverage under all employee benefit programs, plans and
practices as are in effect from time to time and which the Company, makes available from time to time to its senior executive officers, with at least the same opportunity to participate as the other senior executive officers of the Company,
including, without limitation, if applicable, retirement, pension, medical, dental, hospitalization, life insurance, short and long term disability, accidental death and dismemberment and travel accident coverage. 

  
 - 3 - 

 (e) Vacation and Fringe Benefits. Executive shall be entitled to four (4) weeks paid
vacation in each calendar year (pro-rated as necessary for partial calendar years during the Term). Executive may take his vacation at such times consistent with the vacation policies as are in effect from time to time with respect to senior
executive officers. Executive shall be entitled to the perquisites and fringe benefits which the Company makes available from time to time to its senior executive officers, commensurate with Executive’s position with the Company. 

(f) Business Expenses. During the Term, the Company shall reimburse Executive for all reasonable business expenses incurred in the
conduct of Executive’s duties hereunder in accordance with the applicable expense reimbursement policies. 
 3. Termination.

 (a) At-Will Employment. The Company and Executive acknowledge that Executive’s employment is and shall continue to be
“at-will,” as defined under applicable law. This means that it is not for any specified period of time and can be terminated by any of the parties hereto at any time, with or without advance notice (other than as stated herein), and for
any or no particular reason or cause. It also means that Executive’s job duties, title and responsibility, compensation and benefits, as well as the personnel policies and procedures in effect, may be changed with prospective effect, with or
without notice, at any time in the sole discretion of the Company. This “at-will” nature of Executive’s employment shall remain unchanged during Executive’s tenure as an employee and may not be changed, except in an express
writing signed by Executive and a duly authorized member of the Board. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by
this Agreement. 
 (b) Deemed Resignation. Upon termination of Executive’s employment for any reason, Executive shall be deemed
to have resigned from all offices and directorships, if any, then held with the Company or any of its Affiliates, and, at the Company’s request, Executive shall execute such documents as are necessary or desirable to effectuate such
resignations. 
 4. Obligations During and Subsequent to Executive’s Employment. 

(a) Executive’s Obligations. 

(i) Notice Period. Anything in this Agreement notwithstanding, Executive may voluntarily terminate his employment
hereunder upon not less than thirty (30) days prior written notice of Executive delivered to the Company, or upon such shorter notice as Executive and the Company shall agree. 

(ii) Confidentiality. Executive shall not during the Term and thereafter, without the prior written consent of the
Company, knowingly (i) divulge, disclose or make accessible any Confidential Information (as defined below) to any other person, firm, partnership, corporation or other entity or (ii) use any Confidential Information for his own purposes
or for the benefit of any other person, firm, partnership, corporation or other entity (other than the Company), except (x) during the Term, in the business of and for the benefit of the Company or (y) when required to do so by a court of
competent 

  
 - 4 - 

 
jurisdiction, by any governmental agency having supervisory authority over the business of the Company, or by any administrative body or legislative body (including a committee thereof) with
jurisdiction to order Executive to divulge, disclose or make accessible such Confidential Information or by state, federal, foreign or local law, rule or regulation; provided that, in the event that Executive is so required to disclose Confidential
Information, Executive shall, prior to making any such disclosure, provide the Company with prompt written notice of such requirement so that the Company may seek an appropriate protective order. For purposes of this Agreement, “Confidential
Information” shall mean all confidential Company data, analyses, reports, interpretations, forecasts, documents and information concerning the affairs of the Company and its Affiliates, including, without limitation, confidential financial
data, strategic business plans, computer programs and documentation, product development data (or other proprietary product data), customer lists and customer information, discoveries, practices, policies, processes, methods, marketing plans,
prospects, opportunities and other proprietary information and trade secrets in whatever form, tangible or intangible; provided that Confidential Information shall not include (x) information that has become generally available to the public
other than as a result of disclosure by Executive in a manner violative of this Section 4, or (y) information that is rightly received by Executive without restriction on disclosure from a third party legally entitled to possess and
disclose such information without restriction (other than information that Executive may learn or has learned by reason of his association with any Affiliate). Upon conclusion of the Term or at any point prior on request of the Company, Executive
shall immediately return to the Company all Confidential Information, including copies, reproductions and summaries thereof, in his possession and shall erase all such Confidential Information from all media in his possession, and, if the Company so
requests, shall certify in writing that he has done so. All Confidential Information is and shall remain the property of the Company and its Affiliates. 

(iii) Trade Secrets. For purposes of this Agreement, the term “trade secrets,” shall be given its broadest
possible interpretation under applicable law and shall mean all forms and types of financial, business, scientific, technical, economic, or engineering information, including patterns, plans, compilations, program devices, formulas, designs,
prototypes, methods, techniques, processes, procedures, programs, or codes, whether tangible or intangible, and whether or how stored, compiled, or memorialized physically, electronically, graphically, photographically, or in writing that
(i) the Company has taken reasonable measures to keep secret, and that (ii) derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable through proper means by, another
person who can obtain economic value from the disclosure or use of the information. 
 (iv) Non-Competition. During
the Term and twelve (12) months thereafter, Executive agrees that, without the prior written consent of the Board (which the Board may grant or withhold in its discretion): he shall not serve in or otherwise occupy a Competing Position at, or
have any financial interest in, any Competing Entity, except that it will not be deemed a breach of this Section 4(a)(iii) if Executive is an investor or stockholder of not more than two (2%) percent of the equity securities of any entity.

  
 - 5 - 

 (v) Non-Solicitation. During the Term and for twelve (12) months
thereafter, Executive agrees that, without the prior written consent of the Board he shall not, on his own behalf or on behalf of any person or entity, directly or indirectly, (a) solicit for employment any employee who has been employed by the
Company or any Affiliate at any time during the twelve (12) months immediately preceding such solicitation or offer or (b) solicit for the business of or provide services to any client, customer, or vendor of the Company or any Affiliate
for which he or any subordinate provided services during the Term. 
 (vi) Intellectual Property. All Intellectual
Property (as defined below) and Technology (as defined below) created, developed, obtained or conceived of by Executive during the Term, and all business opportunities presented to Executive during the Term shall be owned by and belong exclusively
to the Company, provided that they directly relate to the business of the Company, as of the date of such creation, development, obtaining or conception, and Executive shall (i) promptly disclose to the Company any such Intellectual Property or
Technology or any viable business opportunity presented by a third party to Executive during the Term and which the Company has not rejected and (ii) execute and deliver to the Company, without additional compensation, such instruments (such as
assignments of any Intellectual Property to the Company) as the Company may require from time to time to evidence its ownership of any such Intellectual Property or Technology or business opportunity. For purposes of this Agreement, (x) the
term “Intellectual Property” shall mean and include any and all trademarks, trade names, service marks, service names, patents, copyrights and applications therefor and (y) the term “Technology” shall mean and include any
and. all trade secrets, proprietary information, inventions, discoveries, know-how, formulae, processes and procedures. 

(vii) Non-disparagement. During the Term and at all times thereafter, unless as required by law, including through a
valid subpoena, Executive shall not make, or cause to be made, any statement or communicate any information (whether oral or written) that disparages or reflects negatively on the Company or its Affiliates, officers, directors, board members,
investors, shareholders, agents or employees. 
 (viii) Response to Legal Process. During the Term and twelve
(12) months thereafter, Executive may respond to a lawful and valid subpoena or other legal process but shall give the Company the earliest possible notice thereof, and shall, as much in advance of the return date as possible, make available to
the Company and its counsel the documents and other information sought, and shall assist such counsel with his or her reasonable requests in resisting or otherwise responding to such process. 

  
 - 6 - 

 (ix) Notice Pursuant to Defend Trade Secrets Act. Notwithstanding any
provision of this Agreement prohibiting the disclosure of trade secrets or other Confidential Information, Executive understands that Executive may not be held criminally or civilly liable under any federal or state trade secret law for the
disclosure of a trade secret that (i) is made (A) in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney representing Executive, and (B) solely for the purpose of reporting or
investigating a suspected violation of law, or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Executive files a lawsuit or other court proceeding against
the Company for retaliating against Executive for reporting a suspected violation of law, Executive may disclose the trade secret to the attorney representing Executive and use the trade secret in the court proceeding, so long as Executive files any
document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order. 

(x) Survival of Provisions. The provisions of this Section 4(a) shall survive the termination or expiration of the
applicable Executive’s employment with the Company and shall be fully enforceable thereafter. If it is determined by a court of competent jurisdiction that any restriction in this Section 4(a) is excessive in duration or scope or is
unreasonable or unenforceable under the laws of that jurisdiction, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that
jurisdiction. 
 (xi) Injunctive Relief. Executive and the Company agree that the restrictions contained in Sections
4(a) hereof are a reasonable and necessary protection of the immediate interests on the Company, that any violation of these restrictions would cause substantial injury to the Company and that the Company would not have entered into this Agreement
without receiving the additional consideration offered by Executive in binding himself to these restrictions. In the event of the breach or threatened breach by Executive of any of such restrictions, the Company shall be entitled to apply to any
court of competent jurisdiction for an injunction restraining Executive for such breach or threatened breach, including, but not limited to, a civil seizure order under the Defend Trade Secrets Act; provided that the right of the Company to apply
for an injunction shall not be construed as prohibiting the Company from pursuing any other available remedies for such breach or threatened breach. In the event that, notwithstanding the foregoing, a restriction, or any portion thereof, contained
in Section 4(a) is deemed to be unreasonable by a court of competent jurisdiction, whether due to the passage of time, change of circumstances or otherwise, Executive and the Company agree that such restriction, or portion thereof, shall be
modified in order to make it reasonable and shall be enforced accordingly. 

  
 - 7 - 

 (b) Company’s Obligations. 

(i) Payments of Accrued Obligations upon Termination of Employment. Upon a termination of Executive’s employment
for any reason, Executive (or Executive’s estate or legal representative, as applicable) shall be entitled to receive, within ten (10) days after the date Executive terminates employment with the Company (or such earlier date as may be
required by applicable law): (i) any portion of Executive’s annual base salary earned through Executive’s termination date not theretofore paid, (ii) any expenses owed to Executive under Section 2(f) above, (iii) any
accrued but unused vacation pay owed to Executive pursuant to Section 2(e) above, and (iv) any amount arising from Executive’s participation in, or benefits under, any employee benefit plans, programs or arrangements under
Section 2(d) above, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements. 

(ii) Separation Benefits upon a Covered Termination Other Than During a Change in Control Period. If Executive
experiences a Covered Termination at any time other than during a Change in Control Period, and if Executive executes and does not revoke during any applicable revocation period a general release of all claims against the Company and its Affiliates
in a form acceptable to the Company (a “Release of Claims”) within the sixty (60) day period immediately following Executive’s Separation from Service and in compliance with applicable law, following such Covered
Termination, then in addition to any accrued obligations payable under Section 4(b)(i) above, the Company shall provide Executive with the following: 

(A) Separation Pay. Twelve (12) months (the “Separation Pay Period”) of Executive’s Base
Salary in effect as of Executive’s termination date (the “Separation Pay”). Such amount will be subject to applicable withholdings and payable in twelve equal installments (the “Separation Pay Installments”) on
the first regular payroll date following the date the Release of Claims becomes effective and irrevocable or if the payment is subject to Section 409A, the date set forth in Section 10(a) hereof. 

(B) Bonus. Executive’s Target Bonus Amount in effect as of the termination date, pro-rated based on the total
number of days elapsed in the calendar year as of the termination date, but only if, as of the date of Executive’s termination of employment, the Company and Executive were “on target” to achieve all applicable performance goals for
such discretionary annual bonus as determined by the Board or a committee of the Board in their reasonable discretion; plus any annual discretionary bonus that the Company awarded to Executive in the year prior to the termination but which
Company still had not paid to Executive as of the termination date. Such amount will be subject to applicable withholdings and payable in a single lump sum cash payment on the first regular payroll date following the date the Release of Claims
becomes effective and irrevocable or if the payment is subject to Section 409A, the date set forth in Section 10(a) hereof. 

  
 - 8 - 

 (C) Equity Awards. Each outstanding equity award, including, without
limitation, each stock option held by Executive, shall automatically become vested and, if applicable, exercisable and any forfeiture restrictions shall immediately lapse with respect to seventy-five percent (75%) of the then unvested equity
awards as of the date the Release of Claims becomes effective and irrevocable; provided, however, that if the equity award is subject to Section 409A and payable upon vesting, payment of such equity award shall be made on the date set forth in
Section 10(a) hereof. 
 (D) Continued Healthcare. The Company shall notify Executive of any right to continue
group health plan coverage sponsored by the Company or an Affiliate immediately prior to Executive’s date of termination pursuant to the provisions of applicable law including, but not limited to, the provisions of the Consolidated Omnibus
Budget Reconciliation Act of 1985, as amended (“COBRA”). If Executive elects to receive such continued healthcare coverage, the Company shall directly pay, or reimburse Executive for, the premium for Executive and Executive’ s
covered dependents, less the amount of Executive’s monthly premium contributions for such coverage prior to termination, for the period commencing on the first day of the first full calendar month following the date the Release of Claims
becomes effective and irrevocable through the earlier of (i) the last day of the twelve (12) full calendar months following the date the Release of Claims becomes effective and irrevocable and (ii) the date Executive and
Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s plan(s). Executive shall notify the Company immediately if Executive becomes covered by a group health plan of a subsequent employer.
After the Company ceases to pay premiums pursuant to this subsection, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance the provisions of COBRA or other applicable law. 

(iii) Separation Benefits upon a Covered Termination During a Change in Control Period. If Executive experiences a
Covered Termination during a Change in Control Period, and if Executive executes and does not revoke during any applicable revocation period a Release of Claims within a reasonable period of time specified by the Company, following such Covered
Termination, then in addition to any accrued obligations payable under Section 4(b)(i) above, the Company shall provide Executive with the following: 

(A) Separation Pay. Twelve (12) months of Separation Pay. Such amount will be subject to applicable withholdings
and payable in twelve equal installments on the first regular payroll date following the date the Release of Claims becomes effective and irrevocable or if the payment is subject to Section 409A, the date set forth in Section 10(a) hereof.

  
 - 9 - 

 (B) Bonus. Executive’s Target Bonus Amount in effect as of the
termination date; plus any annual discretionary bonus that the Company awarded to Executive in the year prior to the termination but which Company still had not paid to Executive as of the termination date. Such amount will be subject to
applicable withholdings and payable in a single lump sum cash payment on the first regular payroll date following the date the Release of Claims becomes effective and irrevocable or if the payment is subject to Section 409A, the date set forth
in Section 10(a) hereof. 
 (C) Equity Awards. Each outstanding equity award, including, without limitation,
each stock option held by Executive shall automatically become vested and, if applicable, exercisable and any forfeiture restrictions shall immediately lapse with respect to seventy-five percent (75%) of the then unvested equity awards as of
the date the Release of Claims becomes effective and irrevocable; provided, however, that if the equity award is subject to Section 409A and payable upon vesting, payment of such equity award shall be made on the date set forth in
Section 10(a) hereof. 
 (D) Continued Healthcare. The Company shall notify Executive of any right to continue
group health plan coverage sponsored by the Company or an Affiliate immediately prior to Executive’s date of termination pursuant to the provisions of applicable law including, but not limited to, the provisions of COBRA. If Executive elects to
receive such continued healthcare coverage, the Company shall directly pay, or reimburse Executive for, the premium for Executive and Executive’ s covered dependents, less the amount of Executive’s monthly premium contributions for such
coverage prior to termination, for the period commencing on the first day of the first full calendar month following the date the Release of Claims becomes effective and irrevocable through the earlier of (i) the last day of the twelve
(12) full calendar months following the date the Release of Claims becomes effective and irrevocable and (ii) the date Executive and Executive’s covered dependents, if any, become eligible for healthcare coverage under another
employer’s plan(s). Executive shall notify the Company immediately if Executive becomes covered by a group health plan of a subsequent employer. After the Company ceases to pay premiums pursuant to this subsection, Executive may, if eligible,
elect to continue healthcare coverage at Executive’s expense in accordance the provisions of COBRA or other applicable law. 

(iv) No Other Severance. The provisions of this Section 4(b) shall supersede in their entirety any severance
payment or other arrangement provided by the Company, including, without limitation, any severance plan of the Company. 
 (c) Release of
Claims. The Company shall provide a form Release of Claims to Executive within five (5) business days of Executive’s termination date. 

  
 - 10 - 

 (d) No Requirement to Mitigate; Separation Pay Offset; Survival. 

(i) Executive shall not be required to mitigate the amount of any payment provided for under this Agreement by seeking other
employment or in any other manner. 
 (ii) In the case of Covered Termination Other Than During a Change in Control Period
under Section 4(b)(ii)(A), if Executive accepts a Bona Fide Offer of Employment (as defined below) from another Person during the Separation Pay Period, Executive shall no longer be entitled to each of the twelve (12) Separation Pay
Installments under Section 4(b)(ii)(A). Instead, in addition to the Separation Pay Installments Executive previously paid to Executive: 

(A) If Executive accepts a Bona Fide Offer of Employment on or before the six (6) month anniversary of the Separation Pay
Period, then Executive shall be entitled to an amount equal to six (6) months, less the number of Separation Pay Installments previously paid to Executive; or 

(B) If Executive accepts a Bona Fide Offer of Employment after the six (6) month anniversary of the Separation Pay
Period, then Executive shall not be entitled to receive any further Separation Pay Installments. 
 For the sake of clarity, under no
circumstances shall Executive receive less than six (6) months of Separation Pay in the case of a Covered Termination Other Than During a Change in Control Period. 

(iii) Executive shall notify the Company in writing of Executive’s acceptance of a Bona Fide Offer of Employment within
two (2) business days of such offer. Executive further agrees that the compensation paid in connection with any such Bona Find Offer of Employment will be negotiated in good faith and as the result of arm’s-length bargaining and not with
the effect of diminishing the Company’s right to reduce the Separation Pay under this Agreement. 
 (iv) Notwithstanding
anything to the contrary in this Agreement, the termination of Executive’s employment shall not impair the rights or obligations of any party. 

  
 - 11 - 

 5. Limitation on Payments. Notwithstanding anything in this Agreement to the
contrary, if any payment or distribution Executive would receive pursuant to this Agreement or otherwise (“Payment”) would (a) constitute a “parachute payment” within the meaning of Section 280G of the Internal
Revenue Code of 1986, as amended (the “Code”), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be
determined, before any amounts of the Payment are paid to Executive, which of the following alternative forms of payment would maximize Executive’s after-tax proceeds: (i) payment in full of the entire amount of the Payment (a
“Full Payment”), or (ii) payment of only a part of the Payment so that Executive receives that largest Payment possible without being subject to the Excise Tax (a “Reduced Payment”), whichever of the foregoing
amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such
state and local taxes), results in Executive’s receipt, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion the Payment may be subject to the Excise Tax. 

(a) The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective
date of the Change in Control shall make all determinations required to be made under this Section 5. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, group
or entity effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the
determinations by such independent registered public accounting firm required to be made hereunder. 
 (b) The independent registered public
accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive at such time as requested by the Company or Executive. If the independent
registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Payment, it shall furnish the Company and Executive with an opinion reasonably acceptable to
Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive. 

6. Successors. 

(a) Company’s Successors. Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation,
liquidation or otherwise) to all or substantially all of the Company’s business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the
same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term “Company” shall include any successor to the Company’s business and/or assets
which executes and delivers the assumption agreement described in this Section 6(a) or which becomes bound by the terms of this Agreement by operation of law. 

  
 - 12 - 

 (b) Executive’s Successors. The terms of this Agreement and all rights of Executive
hereunder shall inure to the benefit of, and be enforceable by, Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. 

7. Notices. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed
to have been duly given when personally delivered or one day following mailing via Federal Express or similar overnight courier service. In the case of Executive, mailed notices shall be addressed to Executive at Executive’s home address that
the Company has on file for Executive. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of the Chairman of the Compensation Committee of the Company. 

8. Dispute Resolution. To ensure the timely and economical resolution of disputes that arise in connection with this
Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Agreement, Executive’s employment, or the termination
of Executive’s employment, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in Boston, Massachusetts, conducted by Judicial Arbitration and Mediation Services, Inc.
(“JAMS”) under the applicable JAMS employment rules. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative
proceeding. The arbitrator shall: (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (ii) issue a written arbitration decision, to
include the arbitrator’s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company
shall pay all JAMS’ arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining
injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by
Court action instead of arbitration. 
 9. Miscellaneous Provisions. 

(a) Withholdings and Offsets. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal,
state, local or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on an opinion of counsel if any questions as to the amount or requirement of withholding shall arise. 

  
 - 13 - 

 (b) Waiver. No provision of this Agreement shall be modified, waived or discharged unless
the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive). No waiver by either party of any breach of, or of compliance with, any condition or provision
of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time. 

(c) Whole Agreement. This Agreement represents the entire understanding of the parties hereto with respect to the subject matter hereof
and supersede all prior arrangements and understandings regarding same, including, without limitation, any severance plan of the Company. 

(d) Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the
Commonwealth of Massachusetts. 
 (e) Severability. The finding by a court of competent jurisdiction of the unenforceability,
invalidity or illegality of any provision of this Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or
provision with a valid and enforceable term or provision which most accurately represents the intention of the parties hereto with respect to the invalid or unenforceable term or provision. 

(f) Interpretation; Construction. The headings set forth in this Agreement are for convenience of reference only and shall not be used
in interpreting this Agreement. This Agreement has been drafted by legal counsel representing the Company, but Executive has been encouraged to consult with, and has consulted with, Executive’s own independent counsel and tax advisors with
respect to the terms of this Agreement. The parties hereto acknowledge that each party hereto and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and any rule of construction to the effect that any
ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 
 (g)
Representations; Warranties. Executive represents and warrants that Executive is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that
Executive’s execution and performance of this Agreement will not violate or breach any other agreements between Executive and any other person or entity and that Executive has not engaged in any act or omission that could be reasonably expected
to result in or lead to an event constituting “Cause” for purposes of this Agreement. 
 (h) Counterparts. This Agreement
may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument. 

  
 - 14 - 

 10. Section 409A. The intent of the parties is that the payments and
benefits under this Agreement comply with or be exempt from Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other
guidance that may be issued after the Effective Date, (“Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith. If the Company determines that any
provision of this Agreement would cause Executive to incur any additional tax or interest under Section 409A (with specificity as to the reason therefor), the Company and Executive shall take commercially reasonable efforts to reform such
provision to try to comply with or be exempt from Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Section 409A, provided that any such modifications shall not increase the
cost or liability to the Company. To the extent that any provision hereof is modified in order to comply with or be exempt from Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible,
maintain the original intent and economic benefit to Executive and the Company of the applicable provision without violating the provisions of Section 409A. 

(a) Separation from Service. Notwithstanding any provision to the contrary in this Agreement, no amount that is subject to
Section 409A of the Code shall be payable pursuant to Section 4 unless Executive’s termination of employment constitutes a “separation from service” with the Company within the meaning of Section 409A
(“Separation from Service”) and, except as provided under Section 10(b) of this Agreement, any such amount shall be paid, or in the case of installments, commence payment, on the sixtieth (60th) day following Executive’s Separation from Service. Any installment payments that would have been made to Executive during the sixty (60) day period immediately following
Executive’s Separation from Service but for the preceding sentence shall be paid to Executive on the sixtieth (60th) day following Executive’s Separation from Service and the
remaining payments shall be made as provided in this Agreement. 
 (b) Specified Employee. Notwithstanding any provision to the
contrary in this Agreement, if Executive is deemed at the time of his or her separation from service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion
of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive’s benefits shall not be provided to Executive
prior to the earlier of (a) the expiration of the six (6)-month period measured from the date of Executive’s Separation from Service or (b) the date of Executive’s death. Upon the first day of the seventh month following the date
of the Executive’s separation from service, all payments deferred pursuant to this Section 10(b) shall be paid in a lump sum to Executive, and any remaining payments due under this Agreement shall be paid as otherwise provided herein. 

  
 - 15 - 

 (c) Expense Reimbursements. To the extent that any reimbursements payable pursuant to this
Agreement are subject to the provisions of Section 409A, any such reimbursements payable to Executive pursuant to this Agreement shall be paid to Executive no later than December 31 of the year following the year in which the expense was
incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, and Executive’s right to reimbursement under this Agreement will not be subject to liquidation or exchange
for another benefit. 
 (d) Installments. For purposes of Section 409A (including, without limitation, for purposes of Treasury
Regulation Section 1.409A-2(b)(2)(iii)), Executive’s right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall
at all times be considered a separate and distinct payment. 
 11. Definition of Terms. The following terms referred to
in this Agreement shall have the following meanings: 
 (a) Affiliates. “Affiliates” means any of the Company’s
subsidiaries or joint ventures currently existing or which shall be established during Executive’s employment by the Company. 
 (b)
Bona Fide Offer of Employment. “Bona Fide Offer of Employment” means an offer to provide services in any capacity to another Person that during the first twelve (12) months of providing such services shall entitle Executive to
earn a base salary that equals or exceeds Executive’s annual Base Salary in effect as of his termination date. 
 (c) Cause.
“Cause” means the occurrence of any of the following events, as determined by the Board or a committee designated by the Board, in its sole discretion: (i) Executive’s commission of any felony or any crime involving fraud,
dishonesty or moral turpitude under the laws of the United States or any state thereof; (ii) Executive’s attempted commission of, or participation in, a fraud against the Company; (iii) Executive’s intentional, material violation
of any contract or agreement between Executive and the Company or of any statutory duty owed to the Company, including this Agreement; (iv) Executive’s unauthorized use or disclosure of the Company’s confidential information or trade
secrets; or (v) Executive’s gross misconduct. 
 (d) Change in Control. “Change in Control” means: 

Ownership. Any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total voting power represented by the
Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its Affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related
transactions which the Board of Directors does not approve; or 

  
 - 16 - 

 Merger/Sale of Assets. (A) A merger or consolidation of the Company whether or not
approved by the Board of Directors, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted
into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be,
outstanding immediately after such merger or consolidation; or (B) the sale or disposition by the Company of all or substantially all of the Company’s assets in a transaction requiring stockholder approval Notwithstanding the foregoing, a
“Change in Control” must also constitute a “change in control event” as defined in Treasury Regulation §1.409A-3(i)(5). 

(e) Change in Control Period. “Change in Control Period” means the period beginning with the agreement which if consummated
is a Change in Control and ending twelve (12) months after the effective date of a Change in Control. 
 (f) Covered
Termination. “Covered Termination” shall mean the termination of Executive’s employment (i) by the Company other than for Cause, or (ii) by Executive for Good Reason. 

(g) Competing Entity. “Competing Entity” shall mean (i) the following entities: Ablynx, Affibody, Affilogic, F-Star,
Macrogenics, Merus, Molecular Partners, Xencor; and (ii) any other Person engaged or actively planning to be engaged in the business of developing, manufacturing and marketing next generation protein therapeutics for respiratory, asthma,
autoimmune and oncology conditions. 
 (h) Competing Position. “Competing Position” shall mean engaging, directly or
indirectly, in any manner or capacity (whether for compensation or not), as adviser, principal, agent, affiliate, promoter, partner, officer, director, employee, stockholder, owner, co-owner, consultant, or member of any association or otherwise, in
any Competing Entity. Notwithstanding the foregoing, “Competing Position” shall not include Executive’s employment, engagement, or other association with a Competing Entity in a division, unit or segment of the Competing Entity that
is not engaged or actively planning to be engaged in the business of developing, manufacturing and marketing next generation protein therapeutics for respiratory, asthma, and autoimmune oncology conditions, provided however, that Executive
(i) first provides the Company with a written notice describing in reasonable detail the position with and anticipated activities for the Competing Entity, which written notice also includes an assurance that Executive’s affiliation with
and services for the Competing Entity shall relate only to the non-competitive division, unit or segment and shall not involve any activities that are competitive with the Company, and (ii) Executive’s affiliation with and/or work for the
non-competitive division, unit or segment of the Competing Entity will not require or cause Executive to use or disclose the Company’s Confidential Information. 

  
 - 17 - 

 (i) Good Reason. “Good Reason” means Executive’s resignation from all
positions he or she then holds with the Company if, without Executive’s consent: (i) (A) there is a material diminution in Executive’s duties and responsibilities with the Company or in job title; (B) there is a material
reduction of Executive’s base salary; provided, however, that a material reduction in Executive’s base salary pursuant to a salary reduction program affecting all or substantially all of the employees of the Company and that
does not adversely affect Executive to a greater extent than other similarly situated employees shall not constitute Good Reason; or (C) Executive is required to relocate Executive’s primary work location to a facility or location that
would increase Executive’s one-way commute distance by more than fifty (50) miles from Executive’s primary work location as of immediately prior to such change, (ii) Executive provides written notice outlining such conditions,
acts or omissions to the Company within thirty (30) days immediately following such material change or reduction, (iii) such material change or reduction is not remedied by the Company within thirty (30) days following the
Company’s receipt of such written notice and (iv) Executive’s resignation is effective not later than thirty (30) days after the expiration of such thirty (30) day cure period. 

(j) Good Standing. “Good Standing” means that Executive remains actively employed and (i) has not been given notice of
the termination of employment; (ii) has not given notice of resignation or resigned; (iii) is not suspended by the Company for violation of its material policies and/or procedures and (iv) is not under investigation for conduct that
could, in the Company’s good faith determination, result in a suspension or termination for Cause. 
 (k) “Person”
means without limitation, an individual, a partnership, a limited liability company, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization and a governmental entity or any department, agency
or political subdivision thereof. 
 (Signature page follows) 

  
 - 18 - 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by its duly authorized officer, as of the day and year set forth below. 
  

			
	Pieris Pharmaceuticals, Inc.
		
	By:	 	 /s/ Stephen S. Yoder

	Name:	 	Stephen S. Yoder
	Title:	 	Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ Claude Knopf

	Name:	 	Claude Knopf

 Signature Page to Employment Agreement 

  
 - 19 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]